Compare SRTA & ARVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SRTA | ARVN |
|---|---|---|
| Founded | 2014 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 530.4M | 600.2M |
| IPO Year | 2019 | 2018 |
| Metric | SRTA | ARVN |
|---|---|---|
| Price | $5.49 | $8.48 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 19 |
| Target Price | $7.81 | ★ $15.05 |
| AVG Volume (30 Days) | 680.8K | ★ 684.7K |
| Earning Date | 05-06-2026 | 05-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 242.86 | 58.84 |
| EPS | N/A | ★ 1.70 |
| Revenue | $197,141,000.00 | ★ $262,600,000.00 |
| Revenue This Year | $39.27 | N/A |
| Revenue Next Year | $8.52 | N/A |
| P/E Ratio | ★ N/A | $4.88 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $3.95 | $6.97 |
| 52 Week High | $6.50 | $14.22 |
| Indicator | SRTA | ARVN |
|---|---|---|
| Relative Strength Index (RSI) | 46.16 | 43.83 |
| Support Level | $5.35 | $8.37 |
| Resistance Level | $5.48 | $9.69 |
| Average True Range (ATR) | 0.18 | 0.32 |
| MACD | -0.00 | -0.09 |
| Stochastic Oscillator | 58.89 | 24.38 |
Strata Critical Medical Inc is a time-critical logistics and medical services provider to the U.S. healthcare industry. The group operates one of the nation's air transport and surgical services networks for transplant hospitals and organ procurement organizations, offering an integrated 'One Call' solution for donor organ recovery. It includes two segments: Logistics segments which hold, Air Logistics, Ground Logistics and Organ Placement. The second segment is Clinical Segment which includes: Organ Recovery, Normothermic Regional Perfusion (NRP), and Preservation, and Other Clinical Segment which has Cardiac Care, and Other.
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.